elanoma patients have
- Regression of metastatic lesions in every site to which melanoma
commonly spreads, including to the liver, lung and bone
- Disease control lasting up to 14 months with continuous therapy,
with many responding patients still receiving treatment
- Interim median progression-free survival of at least six months
By contrast, no treatment response was observed in a small group of patients without the BRAF mutation, and progression-free survival was less than two months, consistent with historical data.
Drug-related adverse events, including rash and photosensitivity, have been classified as mild in grade. Serious adverse events, including diagnosis of cutaneous squamous cell carcinoma, were observed in some patients after chronic treatment; however the safety profile has been warranted favourable for this population and the trial authorised to proceed to the next stage of investigation.
The PLX4032 data not only represent an important step forward in understanding and treating malignant melanoma, but also represent a significant advance in the use of biomarkers and diagnostic tools and the potential benefits of tailoring cancer treatment to individual patients.
Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company's clinical stage programs include PLX4032 for the treatment of melanoma and colorectal cancer, PLX5568 for the treatment of polycystic kidney disease and PLX204 for the treatment of diabetes. Among the company's preclinical development programs, candidates are being developed for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases as well as for the treatment of pancreatic and metastatic breast cancer.
PlexxikPage: 1 2 3 4 5 Related medicine technology :1
. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease2
. Encouraging Gene Therapy Results in Genetic Form of Blindness3
. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO4
. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa5
. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium6
. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK27
. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need8
. Actress and Mother Jennifer Garner Kicks Off American Lung Associations Faces of Influenza Awareness Campaign, Encouraging Families to Get Vaccinated Against Influenza9
. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer10
. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results11
. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting